European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Next generation toolbox for greener pharmaceuticals design & manufacturing towards reduced environmental impact

Descrizione del progetto

DE EN ES FR IT PL

Rendere ecologici i farmaci per ridurre l’inquinamento

I farmaci che ci salvano potrebbero finire per danneggiarci se non vengono smaltiti correttamente. Purtroppo, la concentrazione di farmaci nei corsi d’acqua sta raggiungendo livelli pericolosi. In questo contesto, il progetto ENVIROMED, finanziato dall’UE, ridurrà il divario di conoscenze per quanto riguarda l’effetto dei composti farmaceutici e dei loro derivati sull’ambiente. ENVIROMED farà luce sull’impatto ambientale di tali composti lungo tutto il loro ciclo di vita. I risultati forniranno informazioni sulla presenza dei farmaci nell’ambiente, sulla loro persistenza e sul relativo destino ambientale. Il progetto si propone inoltre di sviluppare una serie di tecnologie che consentano una produzione farmaceutica più ecologica e complessivamente più efficiente.

Obiettivo

Pharmaceuticals have undoubtably made our world a better place, ensuring longer and healthier lives. However, pharmaceuticals and their active metabolites are rapidly emerging environmental toxicants. It is thus critical that we fully understand, and mitigate where nec-essary, the environmental impact resulting from their production, use and disposal. In this direction, ENVIROMED addresses two aspects of the environmental impact of pharmaceuticals, a) impact of the processes in manufacturing the compound, and b) impact of the compound itself, during its lifecycle. The project narrows the knowledge gap when it comes to the effect of pharmaceutical compounds, and their derivatives, in the environment as it enables the better understanding the environmental impact of such compounds, throughout their lifecycle. It aims to offer (via extensive monitoring campaigns & scientific studies) information regarding occurrence of pharmaceuticals in the environment, their persistence, environmental fate, and toxicity (via in-vitro & in-vivo models) as well as application of in-silico methods to provide information about the basic risk management and fate prediction in the environment. Brief ideas about toxicity endpoints, available ecotoxicity databases, and expert systems employed for rapid toxicity predictions of ecotoxicity of pharmaceuticals will also be taken into account, in order to have a comprehensive approach to pharmaceuticals' Lifecycle Assessment (LCA). Moreover, the project aims at developing a set of technologies that enable greener and overall, more efficient pharmaceuticals production, which include: a) Green-by-design in-silico drug development; b) Novel sensing to allow reduction of rinsing chemicals and cycles; c) a robust Continuous Biomanufacturing line (CBM), which makes use of AI-enabled process optimisation and prediction, using data assimilation based on chemical sensing and energy disaggregation/monitoring. Training activities and a robust exploitation

Campo scientifico

Parole chiave

Programma(i)

Argomento(i)

Invito a presentare proposte

HORIZON-HLTH-2021-IND-07

Vedi altri progetti per questo bando

Meccanismo di finanziamento

HORIZON-RIA - HORIZON Research and Innovation Actions

Coordinatore

RISA SICHERHEITSANALYSEN GMBH
Contribution nette de l'UE
€ 902 500,00
Indirizzo
XANTENER STRASSE 11
10707 Berlin
Germania

Mostra sulla mappa
PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.
Sì
Regione
Berlin Berlin Berlin
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 902 500,00

Partecipanti (15)

Partner (3)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 2 Agosto 2022

Il mio booklet

Permalink: https://cordis.europa.eu/project/id/101057844/it

European Union, 2024